Download PDF
CC BY 4.0 · Surg J (N Y) 2018; 04(01): e1-e6
DOI: 10.1055/s-0038-1624564
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Use of Ultrasound as a Potential Adjunct to Cell-Free Fetal DNA Screening for Aneuploidy at Weill Cornell Medical College, New York, USA

Jessica Scholl
1   Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York
,
Stephen Chasen
1   Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York
› Author Affiliations
Further Information

Publication History

19 August 2017

15 December 2017

Publication Date:
09 February 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Objective To evaluate the utility of ultrasound in identifying fetuses with uncommon chromosomal abnormalities that would be considered not detectable by cell-free fetal deoxyribonucleic acid (cfDNA).

Study Design We performed a retrospective study of fetuses with chromosomal abnormalities that would be undetectable by cfDNA, who underwent an 11- to 14-week ultrasound from 2006 to 2016.

Results There were 43 pregnancies included. First-trimester ultrasound revealed a fetal abnormality in 19 (44.2%) cases, of which 13 (30.2%) had a thickened nuchal translucency. There were an additional four fetuses with second-trimester sonographic abnormalities. Overall, 23 (53.5%) fetuses were found to have a major anomaly diagnosed by ultrasound. The rate of first-trimester sonographic abnormalities varied widely based on category of chromosomal abnormalities with high rates seen with triploidy (87.5%) and autosomal trisomy (80%) and lower rates seen with structurally abnormal chromosomes (33.3%), trisomy mosaicism (27.3%), other forms of mosaicism (11.1%), and deletions or duplications (25.0%), p < 0.001.

Conclusion The majority of fetuses with uncommon chromosomal abnormalities in our cohort had major sonographic anomalies. The use of first-trimester ultrasound with nuchal translucency measurement may offer utility in identifying fetuses with risk of aneuploidy that would not be detectable with cfDNA.

Keywords

Cell-free fetal DNA - prenatal cytogenetics - fetal ultrasound - nuchal translucency
 

  • References

  • 1 Norton ME, Jelliffe-Pawlowski LL, Currier RJ. Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstet Gynecol 2014; 124 (05) 979-986
    CrossrefPubMedGoogle Scholar
  • 2 Committee Opinion No. Committee opinion no. 640: cell-free DNA screening for fetal aneuploidy. Obstet Gynecol 2015; 126 (03) e31-e37
    CrossrefPubMedGoogle Scholar
  • 3 Norton ME, Baer RJ, Wapner RJ, Kuppermann M, Jelliffe-Pawlowski LL, Currier RJ. Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities. Am J Obstet Gynecol 2016; 214 (06) 727.e1-727.e6
    PubMedGoogle Scholar
  • 4 Malone FD, Canick JA, Ball RH. , et al; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353 (19) 2001-2011
    CrossrefPubMedGoogle Scholar
  • 5 Committee on Practice Bulletins—Obstetrics, Committee on Genetics, and the Society for Maternal-Fetal Medicine. Practice bulletin no. 163: screening for fetal aneuploidy. Obstet Gynecol 2016; 127 (05) e123-e137
    CrossrefPubMedGoogle Scholar
  • 6 Bianchi DW, Parker RL, Wentworth J. , et al; CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014; 370 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 7 Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012; 207 (05) 374.e1-374.e6
    CrossrefPubMedGoogle Scholar
  • 8 Norton ME, Jacobsson B, Swamy GK. , et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015; 372 (17) 1589-1597
    CrossrefPubMedGoogle Scholar
  • 9 Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206 (04) 322.e1-322.e5
    CrossrefPubMedGoogle Scholar
  • 10 Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound Obstet Gynecol 2013; 42 (01) 34-40
    PubMedGoogle Scholar
  • 11 Norton ME, Brar H, Weiss J. , et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207 (02) 137.e1-137.e8
    CrossrefPubMedGoogle Scholar
  • 12 Zimmermann B, Hill M, Gemelos G. , et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012; 32 (13) 1233-1241
    CrossrefPubMedGoogle Scholar
  • 13 Porreco RP, Garite TJ, Maurel K. , et al; Obstetrix Collaborative Research Network. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol 2014; 211 (04) 365.e1-365.e12
    CrossrefPubMedGoogle Scholar
  • 14 Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH. Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities. Fetal Diagn Ther 2014; 35 (03) 174-184
    CrossrefPubMedGoogle Scholar
  • 15 Alamillo CM, Krantz D, Evans M, Fiddler M, Pergament E. Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center. Prenat Diagn 2013; 33 (03) 251-256
    CrossrefPubMedGoogle Scholar
  • 16 Shani H, Goldwaser T, Keating J, Klugman S. Chromosomal abnormalities not currently detected by cell-free fetal DNA: a retrospective analysis at a single center. Am J Obstet Gynecol 2016; 214 (06) 729.e1-729.e11
    CrossrefPubMedGoogle Scholar
  • 17 Gregg AR, Gross SJ, Best RG. , et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013; 15 (05) 395-398
    CrossrefPubMedGoogle Scholar
  • 18 Abuhamad A. Technical aspects of nuchal translucency measurement. Semin Perinatol 2005; 29 (06) 376-379
    CrossrefPubMedGoogle Scholar
  • 19 D'Alton ME, Cleary-Goldman J. Education and quality review for nuchal translucency ultrasound. Semin Perinatol 2005; 29 (06) 380-385
    CrossrefPubMedGoogle Scholar
  • 20 Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinatol 2005; 29 (04) 190-194
    CrossrefPubMedGoogle Scholar
  • 21 Executive Board of the World Health Organization. Birth Defects: Report by the Secretariat. 126th Session. Geneva, Switzerland: World Health Organization; 2009
    Google Scholar
  • 22 Committee on Obstetric Practice, the American Institute of Ultrasound in Medicine, and the Society for Maternal-Fetal Medicine. Committee opinion no. 700: methods for estimating the due date. Obstet Gynecol 2017; 129 (05) e150-e154
    CrossrefPubMedGoogle Scholar
  • 23 von Kaisenberg CS, Fritzer E, Kühling H, Jonat W. Fetal transabdominal biometry at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2002; 20 (06) 564-574
    CrossrefPubMedGoogle Scholar
  • 24 Salomon LJ, Alfirevic Z, Audibert F. , et al; ISUOG Clinical Standards Committee. ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice. Ultrasound Obstet Gynecol 2017; 49 (06) 815-816
    CrossrefPubMedGoogle Scholar
  • 25 Norton ME, Biggio JR, Kuller JA, Blackwell SC. ; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. The role of ultrasound in women who undergo cell-free DNA screening. Am J Obstet Gynecol 2017; 216 (03) B2-B7
    CrossrefPubMedGoogle Scholar
  • 26 Rao RR, Valderramos SG, Silverman NS, Han CS, Platt LD. The value of the first trimester ultrasound in the era of cell free DNA screening. Prenat Diagn 2016; 36 (13) 1192-1198
    CrossrefPubMedGoogle Scholar
  • 27 Reiff ES, Little SE, Dobson L, Wilkins-Haug L, Bromley B. What is the role of the 11- to 14-week ultrasound in women with negative cell-free DNA screening for aneuploidy?. Prenat Diagn 2016; 36 (03) 260-265
    CrossrefPubMedGoogle Scholar
  • 28 Norton ME, Kuppermann M. Women should decide which conditions matter. Am J Obstet Gynecol 2016; 215 (05) 583-587.e1
    PubMedGoogle Scholar